Peking University Health Science Center
北京大学医学部
Hospitals that carry this university's name, added together, plus papers and trials that name only the university.
Research activity, not treatment quality. Not medical advice. How this works
Nasopharyngeal carcinoma
鼻咽癌Led 10 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (23.4%).
- Open trials led
- 0
- Research papers it led
- 10
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Long-term recurrence and brain metastasis of nasopharyngeal carcinoma mimicking cystic radiation encephalopathy relapse: a case report.
- DVH Prediction for VMAT in NPC with GRU-RNN: An Improved Method by Considering Biological Effects.
- A three-miRNA panel in serum: Serving as a novel diagnostic method for nasopharyngeal carcinoma.
- Distribution of regional lymph nodes metastasis in 870 cases of nasopharyngeal carcinoma and the suggestions for individualized elective prophylactic neck irradiation with intensity-modulated radiotherapy.
- Comprehensive single-cell transcriptomic and proteomic analysis reveals NK cell exhaustion and unique tumor cell evolutionary trajectory in non-keratinizing nasopharyngeal carcinoma.
Trials on ClinicalTrials.gov6
- A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
- TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
- Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
- PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
- A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
- To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 90 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.9%).
- Open trials led
- 6
- Research papers it led
- 90
- Trials it led
- 33
- Share of China's trials
- 5.8%
- Share of the world's papers
- 2.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.
- Effectiveness of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screening for Esophageal Cancer in China (ESECC) Randomized Trial.
- Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
- Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
- Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Cli
Trials on ClinicalTrials.gov6
- Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery
- A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
- QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
- Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell Carcinoma
- Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
- Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
Hepatocellular carcinoma
肝细胞癌Led 148 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (5.5%).
- Open trials led
- 9
- Research papers it led
- 148
- Trials it led
- 22
- Share of China's trials
- 1.5%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.
- A Multicenter Randomized Controlled Study of Contrast-enhanced US versus US-guided Biopsy of Focal Liver Lesions.
- Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial.
- NLRP6 deficiency enhances macrophage-mediated phagocytosis via E-Syt1 to inhibit hepatocellular carcinoma progression.
- Methodological challenges in studying immune-suppressive neutrophils in HCC models.
Trials on ClinicalTrials.gov6
- 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma
- Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
- Phase I Study of OriC902 in Treatment of Advanced HCC
Stomach cancer
胃癌Led 323 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (3.9%).
- Open trials led
- 15
- Research papers it led
- 323
- Trials it led
- 79
- Share of China's trials
- 5.4%
- Share of the world's papers
- 1.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, p
- Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer: A Randomized Clinical Trial.
- First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial.
- First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
- Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.
Trials on ClinicalTrials.gov6
- Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers
- The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
- LECS Combined With LSNNS for Early Gastric Cancer (LENS Trial)
- ctDNA-MRD Monitoring After Resection in Gastric Cancer
- Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
- Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
Chordoma
脊索瘤Led 12 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (23.8%).
- Open trials led
- 0
- Research papers it led
- 12
- Trials it led
- 1
- Share of China's trials
- 16.7%
- Share of the world's papers
- 2.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression.
- Complications and local recurrence of chondrosarcoma and chordoma treated by total tumor resection in thoracic and lumbar spine.
- Hypoxia-Inducible Factor-1α (HIF-1α) as a Factor to Predict the Prognosis of Spinal Chordoma.
- Misdiagnosis of primary dumbbell chordoma of the cervical spine.
- CD3L1 expression and its association with the tumor microenvironment in 62 cases of osteosarcoma and Chordoma.
Trials on ClinicalTrials.gov1
Osteosarcoma
骨肉瘤Led 74 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 3
- Research papers it led
- 74
- Trials it led
- 21
- Share of China's trials
- 36.2%
- Share of the world's papers
- 1.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study.
- Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
- Evaluating the Impact of Habitat Analysis via IVIM and DCE-MRI on Neoadjuvant Chemotherapy Outcomes in Osteosarcoma Patients: A Preliminary Study.
- Soft tissue reconstruction of tumor-related proximal tibial hemiarthroplasty using synthetic mesh combined with a medial gastrocnemius flap.
- The clinical outcomes of joint-preserving endoprosthesis reconstruction for primary sarcomas about the knee.
Trials on ClinicalTrials.gov6
- Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
- 68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma
- Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
- ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
- the Exploration of MTAP Deletion in Osteosarcoma by Immunohistochemistry
- B7-H3 NIR Imaging for Osteosarcoma Surgery
Gastrointestinal stromal tumour
胃肠道间质瘤Led 28 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.3%).
- Open trials led
- 3
- Research papers it led
- 28
- Trials it led
- 11
- Share of China's trials
- 14.9%
- Share of the world's papers
- 1.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Long-term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial.
- Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China.
- Risk stratification for 1- to 2-cm gastric gastrointestinal stromal tumors: visual assessment of CT and EUS high-risk features versus CT radiomics analysis.
- Development and validation of a novel diagnostic model for initially clinical diagnosed gastrointestinal stromal tumors using an extreme gradient-boosting machine.
- Mutational landscape of gastrointestinal stromal tumors using next-generation sequencing of a 73-gene panel.
Trials on ClinicalTrials.gov6
- Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
- MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
- Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction
Neuroblastoma
神经母细胞瘤Led 11 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.8%).
- Open trials led
- 0
- Research papers it led
- 11
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Association of genetic variants in m1A modification core genes and neuroblastoma risk.
- Tamibarotene promotes differentiation of neuroblastoma SH-SY5Y cells into neurons, which is associated with activation of the PI3K/AKT signaling pathway.
- Bexarotene Promotes Neuroblastoma SH-SY5Y Cell Differentiation to Mature Neurons with Decreased Proliferation.
- Pathologic changes in neuronal intranuclear inclusion disease are linked to aberrant FUS interaction under hyperosmotic stress.
- Kinase D-interacting Substrate of 220 kDa Is Overexpressed in Gastric Cancer and Associated With Local Invasion.
Trials on ClinicalTrials.gov1
Ewing sarcoma
尤文肉瘤Led 14 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.6%).
- Open trials led
- 2
- Research papers it led
- 14
- Trials it led
- 6
- Share of China's trials
- 37.5%
- Share of the world's papers
- 1.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
- Report and literature review of four cases of EWSR1::NFATC2 round cell sarcoma.
- Radiomics analysis based on CT for the prediction of pulmonary metastases in ewing sarcoma.
- Primary ewing sarcoma in the uterine cervix with multiple bone metastases.
- Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy.
Trials on ClinicalTrials.gov6
- Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma
- Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
- A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
- Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing Sarcoma
- Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment
- Irinotecan and Temozolomide for Ewing Sarcoma
Multiple myeloma
多发性骨髓瘤Led 50 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.8%).
- Open trials led
- 10
- Research papers it led
- 50
- Trials it led
- 16
- Share of China's trials
- 3.3%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
- Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS.
- Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.
- Minimal Clonal Plasma Cell Contamination of Peripheral Stem Cell Grafts Has an Adverse Prognostic Impact in Patients with Multiple Myeloma Undergoing Autologous Transplantation.
- Safety, effectiveness and pharmacokinetics of high-dose propylene glycol-free melphalan (EVOMELA) with a prolonged infusion as myeloablative conditioning in Chinese multiple myeloma patients undergoing autologous stem ce
Trials on ClinicalTrials.gov6
- GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
- ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
- A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
- Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
- 68Ga-BCMA PET/CT in Multiple Myeloma
- KPD Consolidation After ASCT in NDMM Patients
B-cell acute lymphoblastic leukaemia (B-ALL)
B 细胞急性淋巴细胞白血病Led 19 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.9%).
- Open trials led
- 4
- Research papers it led
- 19
- Trials it led
- 4
- Share of China's trials
- 1.6%
- Share of the world's papers
- 1.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Effective MRD clearance and long-term survival with CD19 CAR-T in pediatric B-ALL patients with MRD positivity or chemotherapy intolerance.
- Impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy.
- Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy.
- Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation.
- CD19-Specific CAR-T Cell Treatment of 115 Children and Young Adults with Acute B Lymphoblastic Leukemia: Long-term Follow-up.
Trials on ClinicalTrials.gov6
- Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
- CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
- Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
- Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
- Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
- Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
Aplastic anaemia
再生障碍性贫血Led 30 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (17.2%).
- Open trials led
- 3
- Research papers it led
- 30
- Trials it led
- 5
- Share of China's trials
- 5.1%
- Share of the world's papers
- 1.9%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- BRAF inhibitors enhance erythropoiesis and treat anemia through paradoxical activation of MAPK signaling.
- The Eastern Cooperative Oncology Group Score Rather Than Donor Type Impacts Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients Aged 51-60 Years: A Retrospective Stu
- The outcomes of second haploidentical donor transplantation for graft failure in patients with severe aplastic anaemia.
- Incidence, risk factors and clinical outcomes of primary prolonged isolated thrombocytopenia following haploidentical transplantation for severe aplastic anemia.
- G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Severe Aplastic Anemia Patients.
Trials on ClinicalTrials.gov5
- A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA
- Peripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia
- A Prediction Model in Pregnant Women With Aplastic Anemia
- The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA
- Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA
Haemophagocytic lymphohistiocytosis (HLH)
噬血细胞性淋巴组织细胞增生症Led 9 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (22.3%).
- Open trials led
- 1
- Research papers it led
- 9
- Trials it led
- 1
- Share of China's trials
- 2.1%
- Share of the world's papers
- 0.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Clinical characteristics and prognostic factors in adult macrophage activation syndrome: an observational study in a Chinese cohort.
- Secondary Hemophagocytic Lymphohistiocytosis Syndrome Developing in a Patient With Chronic Lymphocytic Leukemia Under a Long-term Ibrutinib Therapy: A Case Report and Literature Review.
- COX Regression Analysis and Mortality Risk Prediction Model of 85 Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis.
- Prognostic factors in patients with secondary hemophagocytic lymphohistioc ytosis in a Chinese cohort.
- A predictive model for identifying secondary underlying diseases of hemophagocytic lymphohistiocytosis.
Trials on ClinicalTrials.gov3
- Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
- A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))
Haemophilia A
血友病 ALed 3 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (15.8%).
- Open trials led
- 1
- Research papers it led
- 3
- Trials it led
- 1
- Share of China's trials
- 1.2%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Peripheral Blood Lymphocyte Subsets in Factor VIII Inhibitor-Positive Patients with Severe Hemophilia A: A Case-Control Study.
- Single-cell whole-genome sequencing, haplotype analysis in prenatal diagnosis of monogenic diseases.
- Proteomic analysis of MSC-derived apoptotic vesicles identifies Fas inheritance to ameliorate haemophilia a via activating platelet functions.
Trials on ClinicalTrials.gov3
Atypical haemolytic uraemic syndrome
非典型溶血性尿毒症综合征Led 3 of 27 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (11.1%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Atypical Hemolytic Uremic Syndrome-Associated FHR1 Isoform FHR1*B Enhances Complement Activation and Inflammation.
- Whole exome sequencing identifies monogenic forms of nephritis in a previously unsolved cohort of children with steroid-resistant nephrotic syndrome and hematuria.
- Patient-specific iPSC-derived endothelial cells reveal aberrant p38 MAPK signaling in atypical hemolytic uremic syndrome.
Trials on ClinicalTrials.gov2
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led 4 of 64 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.4%).
- Open trials led
- 2
- Research papers it led
- 4
- Trials it led
- 2
- Share of China's trials
- 33.3%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Thrombotic thrombocytopenic purpura following allogeneic hematopoietic stem cell transplantation: a rare but fatal complication.
- Experience in emergency management of first-episode immune thrombotic thrombocytopenic purpura over the past 21 years: a single-center retrospective study.
- Clinical characteristics and treatment response of patients with SLE complicated with thrombotic thrombocytopenic purpura.
- Comparison of clinical characteristics of first-episode thrombotic thrombocytopenic purpura and TTP-like syndrome: a retrospective cohort study in a level I hematology center in China.
Trials on ClinicalTrials.gov2
Fanconi anaemia
范可尼贫血Led 2 of 68 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.8%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led2
- Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group.
- Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patien
Neuromyelitis optica spectrum disorder (NMOSD)
视神经脊髓炎谱系疾病Led 3 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.5%).
- Open trials led
- 1
- Research papers it led
- 3
- Trials it led
- 1
- Share of China's trials
- 1.3%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Clinical characteristics of late-onset neuromyelitis optica spectrum disorder in China.
- Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease.
- Microglial estrogen receptor 1 signal designates sexual dimorphism of AQP4 antibody-induced neuroinflammation and demyelination.
Trials on ClinicalTrials.gov3
IgG4-related disease
IgG4相关性疾病Led 22 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (19.1%).
- Open trials led
- 1
- Research papers it led
- 22
- Trials it led
- 2
- Share of China's trials
- 4.7%
- Share of the world's papers
- 1.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Diagnostic value of a novel salivary gland ultrasound scoring system in IgG4-related sialadenitis.
- Clinical features of IgG4-related retroperitoneal fibrosis among 407 patients with IgG4-related disease: a retrospective study.
- Case Report: A rare case of concurrence of IgG4-related tubulointerstitial nephritis and renal Amyloid A amyloidosis.
- IgG4-related disease presenting with retroperitoneal fibrosis and hypertrophic spinal pachymeningitis: a rare case report and literature review.
- Application of sialography in diagnosis and differential diagnosis of IgG4-related sialadenitis.
Myasthenia gravis
重症肌无力Led 7 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.6%).
- Open trials led
- 0
- Research papers it led
- 7
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Rapid and sustained response to tofacitinib in a patient with anal pyoderma gangrenosum under immunosuppression and bone marrow suppression.
- COVID-19 in patients with myasthenia gravis: a single-center retrospective study in China.
- Risk factors of prolonged ventilation after thymectomy in thymoma myasthenia gravis patients.
- Myasthenia gravis associated with renal cell carcinoma: a paraneoplastic syndrome or just a coincidence.
- Single-Cell Immune Profiling Reveals Neutrophils Promote Myasthenia Gravis Exacerbation Through BAFF Secretion.
Trials on ClinicalTrials.gov1
Moyamoya disease
烟雾病Led 9 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (19.9%).
- Open trials led
- 0
- Research papers it led
- 9
- Trials it led
- 1
- Share of China's trials
- 3.0%
- Share of the world's papers
- 0.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- The impact of anesthesia methods on early postoperative cognitive function in Moyamoya disease patients after vascular bypass surgery.
- Analysis of Optic Disc Morphology and the Peripapillary Retinal and Choroidal Thickness by the Swept Source Optical Coherence Tomography in Patients with Moyamoya Disease.
- Comparison of Changes in Retinal Vascular Parameters and Density in Patients with Moyamoya Disease: A Retrospective Study.
- Analysis of macula structural changes in Moyamoya disease using AI-assisted OCT.
- STC1 downregulation promotes ferroptosis in human brain microvascular endothelial cells: implications for moyamoya disease pathogenesis.
Biliary atresia
胆道闭锁Led 2 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.8%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 1 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.2%).
- Open trials led
- 0
- Research papers it led
- 1
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Takayasu arteritis
大动脉炎Led 5 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (24.6%).
- Open trials led
- 0
- Research papers it led
- 5
- Trials it led
- 2
- Share of China's trials
- 8.0%
- Share of the world's papers
- 0.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Baricitinib for Takayasu arteritis refractory to TNF-α inhibitors: a multicentre, single-arm trial.
- Clinical characteristics and risk factors of coronary artery lesions in chinese pediatric Takayasu arteritis patients: a retrospective study.
- A 16-year-old girl with sudden heart failure and nephrotic syndrome associated with Takayasu's arteritis.
- Age specific clinical manifestations and vascular involvements in childhood-onset Takayasu arteritis.
- The performance of the 2022 ACR/EULAR classification criteria for Takayasu's arteritis as compared to the 1990 ACR classification criteria in a Chinese population.
Trials on ClinicalTrials.gov2
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 10 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 10
- Trials it led
- 1
- Share of China's trials
- 1.4%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Patient journey and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis (IPFLife) in China: a sequential exploratory mixed methods research protocol.
- Clinical and immunological characteristics and prognosis of patients with autoantibody negative dermatomyositis: a case control study.
- Respiratory infection risk in primary Sjögren's syndrome complicated with interstitial lung disease: a retrospective study.
- Pulmonary tuberculosis associated acute fibrinous and organizing pneumonia: A case report and literature review.
- Patterns of Interstitial Lung Disease and Prognosis in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Trials on ClinicalTrials.gov5
- Current Status of Diagnosis, Treatment and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis
- Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 60 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.3%).
- Open trials led
- 2
- Research papers it led
- 60
- Trials it led
- 23
- Share of China's trials
- 41.8%
- Share of the world's papers
- 0.9%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Tetramethylpyrazine Nitrone in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
- Neutrophils Are Associated with Higher Risk of Incident Amyotrophic Lateral Sclerosis in a BMI- and Age-Dependent Manner.
- Amyotrophic Lateral Sclerosis With Concurrent LHON-associated m.14484T>C Mutation: A Case Report and Literature Review.
- Characteristics and influencing factors of pain in amyotrophic lateral sclerosis: a focus on symptom management.
- Unveiling structural damage of the corpus callosum in amyotrophic lateral sclerosis through diffusion tensor imaging and spread direction perspectives.
Trials on ClinicalTrials.gov6
- Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
- Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)
- A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
- The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
- A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
- An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis
Spinal muscular atrophy
脊髓性肌萎缩症Led 1 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (29.1%).
- Open trials led
- 1
- Research papers it led
- 1
- Trials it led
- 2
- Share of China's trials
- 6.7%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Trials on ClinicalTrials.gov6
- Effects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMA
- A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
- Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
- Robot-assisted Training
- Adult Spinal Muscular Atrophy (SMA) China Registry
- Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)
Fabry disease
法布雷病Led 9 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.3%).
- Open trials led
- 0
- Research papers it led
- 9
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 1.0%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Corneal neuro-immune crosstalk in Fabry disease: An in vivo confocal microscopic study.
- Deep learning assisted retinal microvasculature assessment and cerebral small vessel disease in Fabry disease.
- The vestibular and oculomotor dysfunction in Fabry disease: a cohort study in China.
- Inflammatory cytokine expression in Fabry disease: impact of disease phenotype and alterations under enzyme replacement therapy.
- Mutation analysis of the GLA gene in Chinese patients with intracerebral hemorrhage.
Duchenne muscular dystrophy
杜氏肌营养不良Led 14 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.8%).
- Open trials led
- 0
- Research papers it led
- 14
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Interleukin-17B is a new biomarker of human muscle regeneration in dystrophinopathies.
- Single-Nucleus RNA Sequencing Unravels Early Mechanisms of Human Becker Muscular Dystrophy.
- A new pseudoexon activation due to ultrarare branch point formation in Duchenne muscular dystrophy.
- Cryptic exon activation caused by a novel deep-intronic splice-altering variant in Becker muscular dystrophy.
- Characteristics and feasibility of ambulatory respiratory assessment of paediatric neuromuscular disease: an observational retrospective study.
Trials on ClinicalTrials.gov1
Behçet disease
白塞病Led 9 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (22.9%).
- Open trials led
- 1
- Research papers it led
- 9
- Trials it led
- 6
- Share of China's trials
- 35.3%
- Share of the world's papers
- 0.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Comment on: Efficacy and safety of tocilizumab in Behçet's syndrome with refractory arterial lesions: a single-centre observational cohort study in China: reply.
- Correspondence on 'Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease'.
- Uncharted territory: retinal vasculitis and cryoglobulinemia in Behçet's disease - a case report.
- Case Report: A Ticking Time Bomb: Femoral Artery Aneurysm as a Complication of Behcet's Disease in Adolescents.
- Profile of immunological biomarkers in Behcet's syndrome: a large-scale single-center real-world study.
Trials on ClinicalTrials.gov6
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
- A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- AutoInflammatory Disease Alliance Registry (AIDA)
- Corticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym.
- Ivarmacitinib for Refractory Behcet's Syndrome
- Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome
Alport syndrome
Alport 综合征Led 10 of 58 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (17.2%).
- Open trials led
- 0
- Research papers it led
- 10
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 2.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- A retrospective study of kidney disease in Alport syndrome during and after pregnancy.
- Primary membranous nephropathy in two siblings with one combined with anti-glomerular basement membrane disease: a case report.
- Combined Alport syndrome, Klinefelter syndrome and Fanconi syndrome in a Chinese boy.
- mRNA analysis identifies deep intronic variants causing Alport syndrome and overcomes the problem of negative results of exome sequencing.
- Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome.
Trials on ClinicalTrials.gov1
IgA nephropathy
IgA 肾病Led 69 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.4%).
- Open trials led
- 1
- Research papers it led
- 69
- Trials it led
- 5
- Share of China's trials
- 4.2%
- Share of the world's papers
- 4.0%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
- Genetic Determinants of Steroid Responsiveness in IgA Nephropathy.
- Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results.
- Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
- Targeted release of budesonide in primary IgA nephropathy.
Trials on ClinicalTrials.gov6
- To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
- Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
- A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
- A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
- Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Osteogenesis imperfecta
成骨不全症Led 4 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (17.2%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Tibial plateau fracture and RNA sequencing with osteogenesis imperfecta: a case report.
- Familial gigantiform cementoma with recurrent ANO5 p.Cys356Tyr mutations: Clinicopathological and genetic study with literature review.
- A novel mutation in COL1A1 causing osteogenesis imperfecta/hearing loss.
- An Update on Animal Models of Osteogenesis Imperfecta.
Primary biliary cholangitis
原发性胆汁性胆管炎Led 7 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.0%).
- Open trials led
- 0
- Research papers it led
- 7
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Concurrent nonalcoholic fatty liver disease may decrease liver fibrosis severity in patients with primary biliary cholangitis.
- Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients.
- Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis: A meta-analysis.
- Diagnostic Value of Serum Golgi Protein 73 for Liver Inflammation in Patients with Autoimmune Hepatitis and Primary Biliary Cholangitis.
- Endothelial cells expressing CPE and vWF are involved in the Immunopathogenesis of primary biliary cholangitis.
Inherited epidermolysis bullosa
遗传性大疱性表皮松解症Led 7 of 56 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.5%).
- Open trials led
- 0
- Research papers it led
- 7
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.9%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Epidermolysis Bullosa Pruriginosa Treated With Baricitinib.
- Treatment of Recurrent Epidermolysis Bullosa Acquisita With Tofacitinib.
- Dystrophic epidermolysis bullosa characterized by mucosal lesions in a Chinese familial case with a novel compound heterozygous mutation of COL7A1.
- Clinical Features of Paediatric Inflammatory Epidermolysis Bullosa Acquisita: A Case Series Study.
- An intronic variant in LAMB3 contributes to junctional epidermolysis bullosa and enamel hypoplasia via translational attenuation.
Familial adenomatous polyposis
家族性腺瘤性息肉病Led 2 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.2%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led2
- Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019.
- Global, regional, and national disease burden and attributable risk factors of HIV/AIDS in older adults aged 70 years and above: a trend analysis based on the Global Burden of Disease study 2019.